Hsp90-IN-46
Hsp90-IN-46 is a Hsp90 inhibitor. Hsp90-IN-46 exhibits broad-spectrum antiproliferative activity against tumor cell lines. Hsp90-IN-46 inhibits breast cancer cell proliferation by reducing colony formation and downregulating the proliferation marker Ki-67. Hsp90-IN-46 inhibits Hsp90 and its ATPase activity, downregulates the downstream substrate oncoproteins HER2 and CDK4, and moderately induces the heat shock response. Hsp90-IN-46 shows significant antitumor activity in a mouse model of triple-negative breast cancer tumor xenografts. Hsp90-IN-46 can be used for research on various cancers including triple-negative breast cancer, leukemia, non-small cell lung cancer, colon cancer, ovarian cancer, renal cancer, prostate cancer.
For research use only. We do not sell to patients.
- Formula: C21H18BrN5O3
- Molecular Weight:468.30
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
HSP90 |
Hsp90-IN-46 (Compound 13b) (0.01-100 μM; 48 h) exhibits potent, broad-spectrum anticancer activity across 48 human tumor cell lines, with a GI50 value range of 2.17 to 9.60 μM. It achieves total growth inhibition in 26 cell lines and shows extremely low lethality to most cell lines in assays with 5 concentrations applied for 48 h[1].
Hsp90-IN-46 (48 h) exhibits highly active and selective inhibitory effects on MCF-7 and MDA-MB-231 breast cancer cell lines, with IC50 values of 1.33 μM and 1.95 μM, respectively[1].
Hsp90-IN-46 (1-5 μM, 9 days) inhibits the proliferation of MDA-MB-231 breast cancer cells, reduces the expression of the proliferation marker Ki67 in MCF-7 and MDA-MB-231 breast cancer cells, and downregulates the expression of Hsp90 substrate oncoproteins HER2 and CDK4[1].
Hsp90-IN-46 directly inhibits the activity of Hsp90 in an in vitro AlphaLISA-based assay with an IC50 of 12.397 μM, and potently inhibits Hsp90 ATPase activity in a coupled spectrophotometric assay with an IC50 of 0.986 μM[1].
Hsp90-IN-46 (10 μM) induces a moderate heat shock response in HEK-293 cells, increasing the expression level of HspA1A mRNA by 8.7-fold at a concentration of 10 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:48 human tumor cell lines from multiple subpanels (NSCLC, colon, CNS, melanoma, ovarian, renal, prostate, leukemia, breast)
-
Concentration:10 μM
-
Incubation Time:48 h
-
Result:Exhibited a mean growth inhibition (GI%) of 78.84% across 48 cell lines.
Showed strong cytotoxicity (GI% 57.74-68.93%) against NSCLC (NCI-H226), colon (HCC-2998, HT29, SW-620), CNS (SF-539), melanoma (M14), ovarian (OVCAR-3, OVCAR-8), renal (A498, RXF 393), and prostate (DU-145) cancer cell lines.
Demonstrated potent cytotoxicity (GI% 70.24-97.44%) against all leukemia cell lines and most NSCLC, melanoma, colon, CNS, ovarian, renal, and breast cancer cell lines.
Induced 56.97% and 4.33% lethality against melanoma SK-MEL-5 and SK-MEL-2 cell lines, respectively.
-
Cell Line:60 human tumor cell lines
-
Concentration:0.01-100 μM
-
Incubation Time:48 h
-
Result:Demonstrated potent cytotoxicity with GI50 values of 2.17-9.60 μM against 48 cell lines.
Showed lower activity with GI50 values of 10.20-22.70 μM against 12 cell lines.
Induced total growth inhibition (TGI) with values of 6.23-91.00 μM against 26 cell lines (including breast MDA-MB-468, melanoma SK-MEL-5, UACC-62, SK-MEL-2, and ovarian OVCAR-3).
Exhibited minimal toxicity with LC50 >92.5 μM against 57 cell lines, except LC50 values of 27.40-61.30 μM against colon COLO 205 and melanoma SK-MEL-5, UACC-62 cell lines.
Achieved a full-panel GI50 mean graph-midpoint (MG-MID) value of 5.89 μM, with breast cancer MDA-MB-468 as the most sensitive cell line (GI50 = 2.17 μM) and ovarian cancer OVCAR-5 as the least sensitive (GI50 = 22.7 μM).
-
Cell Line:MCF-7, MDA-MB-231, Caco-2, A549 cancer cell lines; normal human skin fibroblast (HSF) cells
-
Concentration:Serial concentrations
-
Incubation Time:48 h
-
Result:Displayed IC50 values of 1.33 μM (MCF-7), 1.95 μM (MDA-MB-231), 4.62 μM (Caco-2), 11.89 μM (A549), and 46.96 μM (HSF).
Achieved selectivity index values of 35.31 (MCF-7), 24.08 (MDA-MB-231), 10.16 (Caco-2), and 3.95 (A549).
-
Cell Line:MDA-MB-231 breast cancer cells
-
Concentration:5 μM
-
Incubation Time:9 days
-
Result:Significantly reduced colony formation from 173 colonies per well (control) to 91 colonies per well.
| Species | Dose | Route | Cmax | Tmax | T1/2 | AUC |
|---|---|---|---|---|---|---|
| Rat[1] | 50 mg/kg | i.p. | 6.74 ± 1.28 μM | 1 h | 2.98 h | 30.68 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice (immunocompromised)[1]
-
Dosage:50 mg/kg
-
Administration:i.p.; daily; 6 consecutive days
-
Result:Reduced MDA-MB-231 xenograft tumor volume and tumor weight by approximately 33%.
Reduced EGFR expression in tumor sections to 0.17-0.92% reaction area.
Maintained stable body weight in treated mice.
Chemical Information
-
Molecular Weight 468.30
-
Formula C21H18BrN5O3
-
SMILES
C/C(NC1=CC=CC=C1NC(/C(C#N)=N/NC2=CC=C(Br)C=C2)=O)=C3C(OCC/3)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Hsp90-IN-46 Related Classifications
HY-181687 Related Classifications
Powered by Bioz